Akebia Therapeutics Q4 Earnings Call Highlights [Yahoo! Finance]
Akebia Therapeutics, Inc. (AKBA)
Last akebia therapeutics, inc. earnings: 3/10 07:49 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.akebia.com/investor-relations
Company Research
Source: Yahoo! Finance
Akebia Therapeutics (NASDAQ:AKBA) executives used the company's fourth-quarter 2025 earnings call to review the first full year of Vafseo's U.S. launch, discuss efforts to build clinical and economic evidence for broader adoption, and outline pipeline plans in rare kidney disease. Management reported $227 million in combined 2025 net product revenue from Vafseo (vadadustat) and Auryxia, while emphasizing that dialysis-provider implementation and patient adherence dynamics influenced Vafseo demand trends in the second half of the year. Vafseo launch: expanding access, improving adherence CEO John Butler said 2025 began “very fast” for Vafseo before “a number of challenges flattened demand in the second half of the year.” He added that the company believes demand growth is beginning to reaccelerate, citing improving dynamics in late 2025 and early 2026. ? Hinge Health's AI Moat Might Be Its Patient Movement Data Butler said that just over a year into launch, more than 1,000 pre
Show less
Read more
Impact Snapshot
Event Time:
AKBA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AKBA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AKBA alerts
High impacting Akebia Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AKBA
News
- Akebia Therapeutics: Q4 Earnings Snapshot [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline Highlights [Yahoo! Finance]Yahoo! Finance
- Akebia Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial and Pipeline HighlightsGlobeNewswire
- Akebia Therapeutics (AKBA) had its price target lowered by BTIG Research from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
AKBA
Earnings
- 2/26/26 - Miss
AKBA
Sec Filings
- 2/26/26 - Form 10-K
- 2/26/26 - Form 8-K
- 2/9/26 - Form SCHEDULE
- AKBA's page on the SEC website